[A19-58] Turoctocog alfa pegol - Benefit assessment according to §35a Social Code Book V
Last updated 04.11.2019
Project no.:
A19-58
Commission:
Commission awarded on 01.08.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency)
Added benefit not proven due to a lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.